ENTA - Company ID 0001177648
ENANTA PHARMACEUTICALS INC trades as ENTA. In its fiscal 2025 annual report the company posted revenue of $65.32M, down 3.4% from the prior year and net income of -$81.89M. This page tracks ENANTA PHARMACEUTICALS INC through 821 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years ENANTA PHARMACEUTICALS INC's revenue declined from $88.27M to $65.32M, a compound annual decline rate of 3.3%. Net profit margin compressed from 24.5% to -125.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Employee stock plan | S-8 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-11 |
| Major company event | 8-K | 2026-03-26 |
| SCHEDULE 13G/A | - | 2026-03-26 |
| Insider trade | 4 | 2026-03-13 |
| Insider trade | 4 | 2026-03-13 |
| Insider trade | 4 | 2026-03-13 |
The largest companies sharing ENANTA PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).
ENANTA PHARMACEUTICALS INC reported revenue of $65.32M for fiscal year 2025, a decrease of 3.4% year over year.
In its latest fiscal year ENANTA PHARMACEUTICALS INC reported a net loss of $81.89M.